Vestipitant
 | |
| Clinical data | |
|---|---|
| ATC code | None |
| Identifiers | |
| |
| CAS Number |
334476-64-1  |
| PubChem (CID) | 9832383 |
| IUPHAR/BPS | 5757 |
| ChemSpider |
8008111  |
| UNII |
S052TOI9BI |
| KEGG |
D06293 |
| ChEMBL |
CHEMBL522987 |
| Chemical and physical data | |
| Formula | C23H21F10N3O |
| Molar mass | 545.416 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (what is this?) (verify) | |
Vestipitant (INN)[1]:98 is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It is under development as a potential antiemetic and anxiolytic drug,[2][3] and as a treatment for tinnitus[4] and insomnia.[5]
See also
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 53" (PDF). World Health Organization. Retrieved 17 November 2016.
- ↑ Reddy, GK; Gralla, RJ; Hesketh, PJ (2006). "Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis". Supportive cancer therapy. 3 (3): 140–2. doi:10.3816/SCT.2006.n.011. PMID 18632487.
- ↑ Brocco, M; Dekeyne, A; Mannoury La Cour, C; Touzard, M; Girardon, S; Veiga, S; De Nanteuil, G; Dejong, TR; et al. (2008). "Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents". European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 18 (10): 729–50. doi:10.1016/j.euroneuro.2008.06.002. PMID 18657401.
- ↑ Clinical trial number NCT00394056 for "Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss" at ClinicalTrials.gov
- ↑ Ratti, E; et al. (December 2013). "Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.". Sleep (2013). 36 (12): 1823–30. doi:10.5665/sleep.3208. PMC 3825431
. PMID 24293756.
This article is issued from Wikipedia - version of the 11/18/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.